{"id":48701,"date":"2025-11-20T15:12:05","date_gmt":"2025-11-20T07:12:05","guid":{"rendered":"https:\/\/flcube.com\/?p=48701"},"modified":"2025-11-20T15:12:07","modified_gmt":"2025-11-20T07:12:07","slug":"regenerons-libtayo-wins-ec-approval-for-adjuvant-cscc-68-risk-reduction","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48701","title":{"rendered":"Regeneron&#8217;s Libtayo Wins EC Approval for Adjuvant CSCC, 68% Risk Reduction"},"content":{"rendered":"\n<p><strong>Regeneron Pharmaceuticals, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/REGN:NASDAQ\">NASDAQ: REGN<\/a>) announced the European Commission (EC) approved <strong>Libtayo (cemiplimab)<\/strong> as adjuvant therapy for adult patients with high\u2011risk cutaneous squamous cell carcinoma (CSCC) post\u2011surgery and radiation, expanding the EU indication to include recurrence\u2011risk patients following the same FDA approval in October 2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Libtayo (cemiplimab)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Regeneron Pharmaceuticals (NASDAQ:\u202fREGN)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>European Commission (EC)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Adjuvant indication expansion<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Adult patients with CSCC at high risk of recurrence after surgery and radiation<\/td><\/tr><tr><td><strong>Previous Approval<\/strong><\/td><td>U.S. FDA approved same indication, Oct\u202f2025<\/td><\/tr><tr><td><strong>Trial Basis<\/strong><\/td><td>Phase\u202fIII C\u2011POST study<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-c-post-phase-3-trial\">Clinical Evidence \u2013 C\u2011POST Phase 3 Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result vs Placebo<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary: Disease recurrence or death<\/strong><\/td><td><strong>68% risk reduction<\/strong> (HR\u202f0.32; 95%\u202fCI:\u202f0.20\u20110.51; p&lt;0.0001)<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>CSCC patients at high risk post\u2011surgery\/radiation<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Consistent with prior Libtayo reports; no new safety signals<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-amp-strategic-impact\">Commercial &amp; Strategic Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Expansion:<\/strong> Adjuvant CSCC represents a <strong>~15,000\u201120,000 patient<\/strong> opportunity annually in the EU5, where Libtayo is now positioned as the first PD\u20111 inhibitor approved in this setting.<\/li>\n\n\n\n<li><strong>Revenue Boost:<\/strong> Analysts project adjuvant CSCC could add <strong>$200\u2011350\u202fmillion<\/strong> to Libtayo\u2019s peak global sales, complementing its <strong>~$1.5\u202fbillion<\/strong> run\u2011rate in advanced CSCC and other indications.<\/li>\n\n\n\n<li><strong>Competitive Moat:<\/strong> First\u2011mover advantage in adjuvant CSCC creates barrier for <strong>Keytruda<\/strong> and <strong>Opdivo<\/strong>, which lack pivotal data in this niche.<\/li>\n\n\n\n<li><strong>Execution:<\/strong> Regeneron will leverage existing EU commercial infrastructure; launch expected Q1\u202f2026 with focused oncology outreach.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Libtayo\u2019s commercial performance, market penetration, and regulatory status. Actual results may differ due to competitive dynamics, reimbursement negotiations, and patient adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the European Commission (EC) approved Libtayo (cemiplimab) as adjuvant&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48702,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1166,18,15,1426],"class_list":["post-48701","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-nasdaq-regn","tag-pd-1-l1","tag-product-approvals","tag-regeneron-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Regeneron&#039;s Libtayo Wins EC Approval for Adjuvant CSCC, 68% Risk Reduction - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the European Commission (EC) approved Libtayo (cemiplimab) as adjuvant therapy for adult patients with high\u2011risk cutaneous squamous cell carcinoma (CSCC) post\u2011surgery and radiation, expanding the EU indication to include recurrence\u2011risk patients following the same FDA approval in October 2025.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48701\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron&#039;s Libtayo Wins EC Approval for Adjuvant CSCC, 68% Risk Reduction\" \/>\n<meta property=\"og:description\" content=\"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the European Commission (EC) approved Libtayo (cemiplimab) as adjuvant therapy for adult patients with high\u2011risk cutaneous squamous cell carcinoma (CSCC) post\u2011surgery and radiation, expanding the EU indication to include recurrence\u2011risk patients following the same FDA approval in October 2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48701\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-20T07:12:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-20T07:12:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2002.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48701#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48701\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Regeneron&#8217;s Libtayo Wins EC Approval for Adjuvant CSCC, 68% Risk Reduction\",\"datePublished\":\"2025-11-20T07:12:05+00:00\",\"dateModified\":\"2025-11-20T07:12:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48701\"},\"wordCount\":279,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48701#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2002.webp\",\"keywords\":[\"NASDAQ: REGN\",\"PD-1\\\/L1\",\"Product approvals\",\"Regeneron Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48701#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48701\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48701\",\"name\":\"Regeneron's Libtayo Wins EC Approval for Adjuvant CSCC, 68% Risk Reduction - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48701#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48701#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2002.webp\",\"datePublished\":\"2025-11-20T07:12:05+00:00\",\"dateModified\":\"2025-11-20T07:12:07+00:00\",\"description\":\"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the European Commission (EC) approved Libtayo (cemiplimab) as adjuvant therapy for adult patients with high\u2011risk cutaneous squamous cell carcinoma (CSCC) post\u2011surgery and radiation, expanding the EU indication to include recurrence\u2011risk patients following the same FDA approval in October 2025.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48701#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48701\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48701#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2002.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2002.webp\",\"width\":1080,\"height\":608,\"caption\":\"Regeneron's Libtayo Wins EC Approval for Adjuvant CSCC, 68% Risk Reduction\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48701#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron&#8217;s Libtayo Wins EC Approval for Adjuvant CSCC, 68% Risk Reduction\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Regeneron's Libtayo Wins EC Approval for Adjuvant CSCC, 68% Risk Reduction - Insight, China&#039;s Pharmaceutical Industry","description":"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the European Commission (EC) approved Libtayo (cemiplimab) as adjuvant therapy for adult patients with high\u2011risk cutaneous squamous cell carcinoma (CSCC) post\u2011surgery and radiation, expanding the EU indication to include recurrence\u2011risk patients following the same FDA approval in October 2025.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48701","og_locale":"en_US","og_type":"article","og_title":"Regeneron's Libtayo Wins EC Approval for Adjuvant CSCC, 68% Risk Reduction","og_description":"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the European Commission (EC) approved Libtayo (cemiplimab) as adjuvant therapy for adult patients with high\u2011risk cutaneous squamous cell carcinoma (CSCC) post\u2011surgery and radiation, expanding the EU indication to include recurrence\u2011risk patients following the same FDA approval in October 2025.","og_url":"https:\/\/flcube.com\/?p=48701","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-20T07:12:05+00:00","article_modified_time":"2025-11-20T07:12:07+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2002.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48701#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48701"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Regeneron&#8217;s Libtayo Wins EC Approval for Adjuvant CSCC, 68% Risk Reduction","datePublished":"2025-11-20T07:12:05+00:00","dateModified":"2025-11-20T07:12:07+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48701"},"wordCount":279,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48701#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2002.webp","keywords":["NASDAQ: REGN","PD-1\/L1","Product approvals","Regeneron Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48701#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48701","url":"https:\/\/flcube.com\/?p=48701","name":"Regeneron's Libtayo Wins EC Approval for Adjuvant CSCC, 68% Risk Reduction - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48701#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48701#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2002.webp","datePublished":"2025-11-20T07:12:05+00:00","dateModified":"2025-11-20T07:12:07+00:00","description":"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the European Commission (EC) approved Libtayo (cemiplimab) as adjuvant therapy for adult patients with high\u2011risk cutaneous squamous cell carcinoma (CSCC) post\u2011surgery and radiation, expanding the EU indication to include recurrence\u2011risk patients following the same FDA approval in October 2025.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48701#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48701"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48701#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2002.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2002.webp","width":1080,"height":608,"caption":"Regeneron's Libtayo Wins EC Approval for Adjuvant CSCC, 68% Risk Reduction"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48701#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Regeneron&#8217;s Libtayo Wins EC Approval for Adjuvant CSCC, 68% Risk Reduction"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2002.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48701","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48701"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48701\/revisions"}],"predecessor-version":[{"id":48703,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48701\/revisions\/48703"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48702"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48701"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48701"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48701"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}